Form 4: Atara Biotherapeutics Insider Acquires Additional Shares

Panacea Innovation Ltd and Director James Huang have acquired 19,335 shares of Atara Biotherapeutics, Inc. common stock for approximately $186,300, increasing their indirect beneficial ownership to 1,350,000 shares.

Summary

• Panacea Innovation Ltd and James Huang, a Director and 10% owner of Atara Biotherapeutics, Inc. (ATRA), acquired 19,335 shares of common stock.
• The transaction occurred on July 17, 2025, at a price of $9.6391 per share, totaling approximately $186,300.
• Following this purchase, the reporting persons indirectly beneficially own 1,350,000 shares of Atara Biotherapeutics common stock.
• The shares are held by Panacea Venture Healthcare Fund II, L.P., with Panacea Innovation Limited and James Huang disclaiming beneficial ownership despite their control over the general partners of the fund.

Sentiment

Score: 8

Explanation: The insider purchase by a significant shareholder and director indicates strong confidence in the company's prospects, which is a positive sentiment.

Positives

• A significant insider purchase by a 10% owner and Director, Panacea Innovation Ltd and James Huang, signals confidence in the company's future prospects.
• The acquisition of 19,335 shares at $9.6391 per share represents a direct investment of approximately $186,300 by key stakeholders.

Future Outlook

The document does not provide explicit forward-looking statements or guidance beyond the details of the transaction itself.

Industry Context

This insider purchase by a significant shareholder and director in a biotechnology company suggests a positive internal view of the company's future, which can be a notable signal in the often volatile biotech sector.

Related Party Transactions

• The transaction involves the acquisition of shares by Panacea Innovation Ltd and James Huang, who are a 10% owner and Director of Atara Biotherapeutics, Inc., making it a related party transaction.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive indicator of future stock performance, potentially increasing investor confidence.
• The transaction reinforces the alignment of interests between significant owners/management and other shareholders.

Key Dates

Recommendation

Keywords

Atara Biotherapeutics, ATRA, Panacea Innovation, James Huang, Insider Trading, SEC Form 4, Stock Purchase, Biotechnology, Healthcare Investment